Company
Who we are
What we do
Investor relations
News & key figures
Investor presentation
Xlife dates
ESG
Projects
Technology Platforms
Biotech and Therapies
Medical Technology
Artificial Intelligence
Contact
DE
Collaborative
Analyst coverage
Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
69.8 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view
News
Press Releases
23.1.23
Stifel initiates research coverage of Xlife Sciences
20.1.23
Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent Office
16.1.23
Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)
Archive
Ad hoc News
21.11.2022
Xlife Sciences initiates a review of strategic options
28.9.2022
Xlife Sciences with pleasing progress in the first half of 2022
9.5.2022
Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario
Archive
Downloads
Financial Reports
September 28, 2022
Half-Year Report 2022
May 9, 2022
Xlife Sciences AG Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement
Sign up for our media releases